Table 2.
Pathologic characteristics and FISH results of all 222 specimens compared across different biopsy types (fine needle aspiration biopsy, core needle biopsy, and excisional biopsy) with p values.
| Fine needle aspiration biopsy |
Core needle biopsy | Excisional biopsy | P value | |
|---|---|---|---|---|
| Number | 46 | 112 | 64 | |
| Age (mean (SD)) | 64.47 (15.70) | 65.00 (16.66) | 60.38 (15.81) | 0.178 |
| Gender (%) | 0.209 | |||
| Female | 19 (41.3) | 42 (37.5) | 31 (48.4) | |
| Male | 27 (58.7) | 70 (62.5) | 33 (51.6) | |
| Data Access Group (%) | <0.001 | |||
| MGH | 2 (4.3) | 19 (17.0) | 6 (9.4) | |
| MSKCC | 4 (8.7) | 12 (10.7) | 0 (0.0) | |
| SFVAHCS | 6 (13.0) | 6 (5.4) | 1 (1.6) | |
| Stanford | 20 (43.5) | 66 (58.9) | 54 (84.4) | |
| UCSF | 14 (30.4) | 7 (6.2) | 3 (4.7) | |
| UVA | 0 (0.0) | 2 (1.8) | 0 (0.0) | |
| Indication (%) | <0.001 | |||
| Additional diagnostic tissue | 1 (2.2) | 15 (13.4) | 27 (42.2) | |
| Additional tissue for ancillary studies |
0 (0.0) | 1 (0.9) | 2 (3.1) | |
| Clinical trial | 0 (0.0) | 1 (0.9) | 0 (0.0) | |
| Initial diagnosis | 27 (58.7) | 38 (33.9) | 11 (17.2) | |
| Other/unknown | 0 (0.0) | 2 (1.8) | 0 (0.0) | |
| R/o recurrence | 10 (21.7) | 19 (17.0) | 7 (10.9) | |
| R/o transformation | 7 (15.2) | 36 (32.1) | 15 (23.4) | |
| Staging | 1 (2.2) | 0 (0.0) | 2 (3.1) | |
| Tissue site (%) | 0.832 | |||
| Bone | 1 (2.2) | 6 (5.4) | 2 (3.1) | |
| Lymph node or related | 29 (63.0) | 60 (53.6) | 41 (64.1) | |
| Mediastinum | 1 (2.2) | 6 (5.4) | 2 (3.1) | |
| Organ | 7 (15.2) | 23 (20.5) | 7 (10.9) | |
| Other or unknown | 1 (2.2) | 2 (1.8) | 2 (3.1) | |
| Soft tissue | 7 (15.2) | 15 (13.4) | 10 (15.6) | |
| Final WHO diagnosis (%) | 0.206 | |||
| Burkitt | 1 (2.2) | 3 (2.7) | 1 (1.6) | |
| DLBCL | 31 (67.4) | 85 (75.9) | 57 (89.1) | |
| HGBCL | 4 (8.7) | 3 (2.7) | 2 (3.1) | |
| HGBCL-MYC/BCL2 | 7 (15.2) | 10 (8.9) | 2 (3.1) | |
| Other/unknown | 3 (6.5) | 8 (7.1) | 0 (0.0) | |
| PMLBCL | 0 (0.0) | 2 (1.8) | 1 (1.6) | |
| TCHRLBCL | 0 (0.0) | 1 (0.9) | 1 (1.6) | |
| MYC FISH (%) | 0.527 | |||
| negative | 33 (71.7) | 86 (76.8) | 55 (85.9) | |
| not done | 0 (0.0) | 0 (0.0) | 1 (1.6) | |
| positive | 11 (23.9) | 21 (18.8) | 7 (10.9) | |
| unsuccessful | 1 (2.2) | 3 (2.7) | 0 (0.0) | |
| variant 3’ signal loss | 1 (2.2) | 1 (0.9) | 1 (1.6) | |
| variant extra 5’ signaling | 0 (0.0) | 1 (0.9) | 0 (0.0) | |
| BCL2 FISH (%) | 0.274 | |||
| extra BCL2 signal on add(3) | 0 (0.0) | 0 (0.0) | 1 (1.6) | |
| negative | 28 (60.9) | 60 (53.6) | 41 (64.1) | |
| not done | 6 (13.0) | 14 (12.5) | 2 (3.1) | |
| positive | 12 (26.1) | 36 (32.1) | 20 (31.2) | |
| unsuccessful | 0 (0.0) | 2 (1.8) | 0 (0.0) | |
| BCL6 FISH (%) | 0.718 | |||
| negative | 31 (67.4) | 70 (63.1) | 40 (62.5) | |
| not done | 7 (15.2) | 20 (18.0) | 9 (14.1) | |
| positive | 8 (17.4) | 18 (16.2) | 13 (20.3) | |
| unsuccessful | 0 (0.0) | 2 (1.8) | 0 (0.0) | |
| variant 5’ signal loss | 0 (0.0) | 1 (0.9) | 2 (3.2) |
CNB (core needle biopsy), DLBCL (diffuse large B-cell lymphoma), EB (excisional biopsy), FNAB (fine needle aspiration biopsy), HGBCL (high-grade B-cell lymphoma, NOS), HGBCL-MYC/BCL2 (high-grade B-cell lymphoma with MYC and BCL2 rearrangements), PMLBCL (primary mediastinal large B-cell lymphoma), TCHRLBCL (T-cell, histiocytic-rich large B-cell lymphoma), MGH (Massachusetts General Hospital), MSKCC (Memorial Sloan Kettering Cancer Center), SFVAHCS (San Francisco Veterans Administration Health Care System), UCSF (University of California San Francisco, UVA (University of Virginia).